Radioligand theranostics (RT) in oncology use cancer-type specific biomarkers and molecular imaging (MI), including positron emission tomography (PET), single-photon emission computed tomography (SPECT) and planar scintigraphy, for patient diagnosis, therapy, and personalized management. While the definition of theranostics was initially restricted to a single compound allowing visualization and therapy simultaneously, the concept has been widened with the development of theranostic pairs and the combination of nuclear medicine with different types of cancer therapies. Here, we review the clinical applications of different theranostic radiopharmaceuticals in managing different tumor types (differentiated thyroid, neuroendocrine prostate, and breast cancer) that support the combination of innovative oncological therapies such as gene and cell-based therapies with RT.
Notes
Funding: This work was partly funded by the Horizon 2020 Programme under grant agreement
no 675417 (PET3D) and the Herbert-Worch-Stiftung. Additionally, this work was supported by a
Collaboration Grant of the Medical Faculty of the University of Bonn between CIO UKB and the
Johanniter Hospital.
Acknowledgments: This review was supported by the Immune-Image consortium. The Immune-
Image project receives funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU)
under grant agreement No 831514 (Immune-Image). The JU receives support from the European
Union's Horizon 2020 research and innovation programme and EFPIA.
